Evidence map›Paper›PMID 42634464›Full record

ReviewZhongguo fei ai za zhi = Chinese journal of lung cancer2026

[Abnormally Elevated Procalcitonin in Stage IV Lung Adenocarcinoma 
with Neuroendocrine Differentiation: A Case Report and Literature Review].

Yongquan Pan, Ting Wu, Jinfeng Jiang, Tianyu Sun, Chenyang Liu, Hao Ding

Abstract readCase ReportsReviewEnglish Abstract
PubMed Full text at PMC Publisher
In one paragraph

Review in Zhongguo fei ai za zhi = Chinese journal of lung cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Yongquan PanDepartment of Respiratory and Critical Care Medicine, Affiliated People's Hospital of Jiangsu University, Zhenjiang 212002, China.
Ting WuDepartment of Pathology, Affiliated People's Hospital of Jiangsu University, Zhenjiang 212002, China.
Jinfeng JiangDepartment of Respiratory and Critical Care Medicine, Affiliated People's Hospital of Jiangsu University, Zhenjiang 212002, China.
Tianyu SunDepartment of Respiratory and Critical Care Medicine, Affiliated People's Hospital of Jiangsu University, Zhenjiang 212002, China.
Chenyang LiuDepartment of Respiratory and Critical Care Medicine, Affiliated People's Hospital of Jiangsu University, Zhenjiang 212002, China.
Hao DingDepartment of Respiratory and Critical Care Medicine, Affiliated People's Hospital of Jiangsu University, Zhenjiang 212002, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Procalcitonin (PCT) is a key biomarker widely used in clinical practice for the diagnosis of bacterial infection, assessment of antimicrobial efficacy, and prognostic evaluation. Studies have shown that PCT can also be elevated in various malignancies, correlating closely with tumor progression, metastasis, and poor prognosis. However, the value of PCT in monitoring disease status and treatment response in non-small cell lung cancer (NSCLC) remains unclear. This article reports a case of a patient with previously treated stage IV lung adenocarcinoma with neuroendocrine differentiation, who presented with a marked elevation in serum PCT in the absence of active infection. Following local radiotherapy to the pleural metastatic lesion, the PCT level declined rapidly. This report aims to explore the potential clinical significance of PCT in NSCLC with neuroendocrine differentiation and to provide a reference for disease assessment and prognostic evaluation in patients with similar symptoms.
.

Indexed as

AdenocarcinomaLung NeoplasmsProcalcitoninAdenocarcinoma of LungCell DifferentiationHumansMaleMiddle AgedNeoplasm StagingProcalcitoninLung neoplasmsNeuroendocrine differentiationProcalcitoninPrognosisTreatment response monitoring

Identifiers

PMID42634464
PMCPMC13482759

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.